← Leaderboards
Chengguo Xing
University Of Minnesota
$6,408,898
Attributed
$7,416,049
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,962,893 · 14
By mechanism
U54$6,671,383 · 4
R01$5,036,829 · 4
R33$984,579 · 1
R61$822,159 · 1
R03$446,903 · 3
P41$1,040 · 1
Top collaborators
- John David Carpten8 shared
- Romonia Renee Reams8 shared
- Kinfe Ken Redda8 shared
- Mariana C Stern8 shared
- Diana J Wilkie8 shared
- Carol A. Mathews3 shared
- Ramzi George Salloum2 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Stephen S Hecht$48,780,026
- Irina Stepanov$11,468,606
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsBasePathway InteractionsPreventReportingSuccessFutureIn VivoKavaGrantSmokerEvaluationA/J MouseFoundationsMalignant Neoplasm Of LungChemopreventive AgentPreparationConsumptionBiologicalChemopreventionIncidenceDoseLeadInsight
Grant awards (42)
The potential of kava in enabling tobacco cessation - its holistic effects in managing stress and insomnia associated with abstinence$461,592
R33 · FY2025 · AT · contact PI
The potential of kava in enabling tobacco cessation - its holistic effects in managing stress and insomnia associated with abstinence$522,987
R33 · FY2023 · AT · contact PI
Quantifying NNK metabolites to facilitate Kava lung cancer prevention clinical translation$76,250
R03 · FY2023 · CA · contact PI
3/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center$1,118,428
U54 · FY2022 · CA
1/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center$994,198
U54 · FY2022 · CA
Admin-Core-001$124,539
U54 · FY2022 · CA
African Bi-Costal (ABC) Cancer Study$124,539
U54 · FY2022 · CA
Quantifying NNK metabolites to facilitate Kava lung cancer prevention clinical translation$76,250
R03 · FY2022 · CA · contact PI
3/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center$1,141,251
U54 · FY2021 · CA
2/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center$1,054,792
U54 · FY2021 · CA
1/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center$891,935
U54 · FY2021 · CA
2/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center$1,221,701
U54 · FY2020 · CA
A phased clinical trial of a dietary supplement kava: biomarker changes and anxiolytic effects$375,597
R61 · FY2020 · AT · contact PI
Admin Supp for A phased clinical trial of a dietary supplement kava: biomarker changes and anxiolytic effects$68,221
R61 · FY2020 · AT · contact PI
A phased clinical trial of a dietary supplement kava: biomarker changes and anxiolytic effects$378,341
R61 · FY2019 · AT · contact PI
Dihydromethysticin (DHM) for Lung Cancer Chemoprevention$300,682
R01 · FY2019 · CA · contact PI
Dihydromethysticin (DHM) for Lung Cancer Chemoprevention$315,944
R01 · FY2018 · CA · contact PI
Dihydromethysticin (DHM) for Lung Cancer Chemoprevention$84,923
R01 · FY2018 · CA · contact PI
Dihydromethysticin (DHM) for Lung Cancer Chemoprevention$316,616
R01 · FY2017 · CA · contact PI
Mechanisms of Anticancer Agents Selective against Drug Resistant Leukemia$258,849
R01 · FY2016 · CA · contact PI
Dihydromethysticin (DHM) for Lung Cancer Chemoprevention$249,013
R01 · FY2016 · CA · contact PI
Dihydromethysticin (DHM) for Lung Cancer Chemoprevention$98,687
R01 · FY2016 · CA · contact PI
Mechanisms of Anticancer Agents Selective against Drug Resistant Leukemia$48,280
R01 · FY2016 · CA · contact PI
Dihydromethysticin (DHM) for Lung Cancer Chemoprevention$347,700
R01 · FY2015 · CA · contact PI
Mechanisms of Anticancer Agents Selective against Drug Resistant Leukemia$306,280
R01 · FY2015 · CA · contact PI
Mechanisms of Anticancer Agents Selective against Drug Resistant Leukemia$297,092
R01 · FY2014 · CA · contact PI
Developing a Post-carcinogen Lung Cancer Chemopreventive Agent$200,000
R01 · FY2014 · CA · contact PI
Mechanisms of Anticancer Agents Selective against Drug Resistant Leukemia$287,903
R01 · FY2013 · CA · contact PI
Developing a Post-carcinogen Lung Cancer Chemopreventive Agent$200,000
R01 · FY2013 · CA · contact PI
Mechanisms of Anticancer Agents Selective against Drug Resistant Leukemia$306,280
R01 · FY2012 · CA · contact PI
Developing a Post-carcinogen Lung Cancer Chemopreventive Agent$200,000
R01 · FY2012 · CA · contact PI
An NF-kB inhibitor as a post-carcinogen lung cancer chemopreventive agent$71,689
R03 · FY2012 · CA · contact PI
Developing a Post-carcinogen Lung Cancer Chemopreventive Agent$200,000
R01 · FY2011 · CA · contact PI
An NF-kB inhibitor as a post-carcinogen lung cancer chemopreventive agent$73,214
R03 · FY2011 · CA · contact PI
Developing a Post-carcinogen Lung Cancer Chemopreventive Agent$200,000
R01 · FY2010 · CA · contact PI
Bcl-2 selective inhibitors: development and application to cancer treatment$203,428
R01 · FY2009 · CA · contact PI
Bcl-2 selective inhibitors: development and application to cancer treatment$203,450
R01 · FY2008 · CA · contact PI
Identification of Chemopreventive Agents Against Lung Tumorigenesis$74,750
R03 · FY2008 · CA · contact PI
Bcl-2 selective inhibitors: development and application to cancer treatment$203,470
R01 · FY2007 · CA · contact PI
Identification of Chemopreventive Agents Against Lung Tumorigenesis$74,750
R03 · FY2007 · CA · contact PI
VALIDITY OF THE AFFECTED DISCORDANT-SIB-PAIR DESIGN$1,040
P41 · FY2007 · RR · contact PI
Bcl-2 selective inhibitors: development and application to cancer treatment$208,232
R01 · FY2006 · CA · contact PI